NeuroOne Medical Technologies Corp (NASDAQ: NMTC) claims to be crafting 'highly-sensitive tape recorders' for the brain, and even tools to remove problematic tissue. Sounds fascinating, doesn't it? Or do you think it's complete BS? One thing that we do know is real is the stock's recent price action…shares have shot up by 50% over the last two weeks. Is this run just the beginning or just a well crafted pump? NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) 1-month trading range: $1.00- $1.54 Typical average daily volume: 206K Float: ~ 13.5 million NeuroOne Medical Technologies Corp.Business Think of it as a workshop constantly crafting and refining tools for the brain and nervous system. NeuroOne Medical Technologies core specialty lies in thin film electrode technology. This sounds fancy, but essentially, it's like a highly sensitive tape recorder for your brain, continually reading and interpreting electrical signals. The technology is used in two kinds of recording procedures - continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG). These high-tech methods monitor the brain's electrical activity over extended periods, sort of like a surveillance system for your brain. They also work on spinal cord and brain stimulation tools, and devices for a medical procedure called ablation, which is a way of treating diseases by selectively eliminating the problematic tissue. All these developments aim to help patients with neurological disorders such as epilepsy, and Parkinson's disease and even people with chronic pain caused by unsuccessful back surgeries, among other conditions. Teaming up with RBC Medical Innovations, they're trying to develop a radio frequency ablation generator, a device that uses radio waves to heat up and destroy troublesome areas in the body, while leaving the healthy parts intact. 
Source: NeuroOne While the promises of NeuroOne sound fascinating, as with any medical technology, effectiveness will ultimately be proven through rigorous clinical testing and real-world use. On June 12, the company submitted a 510(k) Application to the FDA for OneRF Ablation System. Essentially, NeuroOne developed a method to use their already installed electrodes (sEEG) to continuously monitor this 'circuit board', and pinpoint any abnormal activity. Once detected, the OneRF™ system can connect these electrodes to a special radio frequency (RF) generator, safely removing the problematic nervous tissue. If the FDA gives the green light, this will be NeuroOne's first step towards introducing this unique RF ablation system in the world of neurology and neurosurgery But remember, this is just a submission and not an approval. There are still several checkpoints to cross before this technology can hit the market. It's a hopeful start, though, and potentially a new avenue to treat neurological disorders. Financials Source: Stockanalysis.com NMTC is experiencing strong revenue growth, going from $2.1 million in 2022 to $4.0 million over the last twelve months. However, substantial operating expenses have led to consistent operating losses. The company is far from being profitable. In addition, cash is a concern. Its negative free cash flow indicates the company spends way more than it's bringing in. Again, it's not all negative. The firm's total assets are growing…but so are its liabilities. But what's really frustrating for investors is that the company is issuing new shares and diluting current shareholders. Promoter Activity I heard about NMTC via email from one promoter. Here were their main selling points on the stock: - NMTC has a low float of shares, which suggests the potential for high volatility and opportunities for quick gains.
- The company has recently submitted a 510(k) application to the FDA for its OneRF™ Ablation System, a transformative medical device. If approved, it could bring significant attention and market buzz to NMTC.
- The trend has been bullish lately, as the stock has climbed from $1 to as high as $1.54 in recent trading.
- The company's innovative technologies, such as the OneRF™ Ablation System and the Evo® Depth Electrode, are potentially disruptive in the medical field, specifically neurology, indicating future growth potential.
- The company's patented technologies have wide-ranging applications in treating various neurological and psychiatric conditions. This versatility adds to its growth potential in the medical device industry.
The investor awareness campaign ran from 7/07 to 7/10. They received $8K for their efforts. However, they've worked together in the past, and in total, have snagged $465K from NMTC. Straight to the Facts NMTC has been trading well lately. However, it hasn't seen a lot of volume. Also, given its massive run up…it wouldn't be surprising if we see an offering soon. Keep it on your watchlist…look for catalysts…and a spike in volume. If you do decide to trade this, it would likely be wise to NOT hold overnight…in case they decide to raise cash and dilute shareholders. Always at your service, Baron Von Stocks | 
Post a Comment
Post a Comment